Last reviewed · How we verify
JS1-1-01 high-dose group
At a glance
| Generic name | JS1-1-01 high-dose group |
|---|---|
| Also known as | JS1-1-01 tablet ; JS1-1-01 placebo tablet, JS1-1-01 pills; Duloxetine hydrochloride placebo capsules |
| Sponsor | Tasly Pharmaceutical Group Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression (PHASE2, PHASE3)
- A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JS1-1-01 high-dose group CI brief — competitive landscape report
- JS1-1-01 high-dose group updates RSS · CI watch RSS
- Tasly Pharmaceutical Group Co., Ltd portfolio CI